In Tight Times, Companies Fill the Funding Gap  by Savage, Neil
Leading Edge
AnalysisIn Tight Times, Companies Fill the
Funding GapWith federal budgets under pressure, scientists turn to corpora-
tions for research support.Earlier this year, Senator ElizabethWarren
introduced a bill that she said would pro-
vide billions of new dollars for medical
research. The Massachusetts Democrat
proposed that if large pharmaceutical
companies are caught breaking laws,
any settlements they reach with the fed-
eral government should include paying
into a fund that would benefit the NIH.
Warren says that such a ‘‘swear jar,’’ as
she calls her Medical Innovation Act,
would have provided roughly $6 billion a
year to the NIH research budget had it
been the law over the last five years.
Pharmaceutical companies oppose the
measure, and it’s not clear that it will pass.
But it does call attention to a problem
people in the biomedical research field
agree exists, a shrinking pool of govern-
ment money for funding science. Though
Congress doubled the NIH budget be-
tween 1998 and 2003, it’s been contract-
ing ever since, dropping by more than
22 percent in inflation-adjusted dollars,
according to the Federation of American
Societies for Experimental Biology. Public
funding for scientific research has drop-ped in Europe as well, as governments
imposed austerity measures in response
to the 2008 fiscal crisis. ‘‘I think all coun-
tries are struggling with their budgets,’’
says Birgitte Nauntofte, executive direc-
tor of the Novo Nordisk Foundation in
Hellerup, Denmark. ‘‘I have not heard of
a country that’s not struggling.’’
So researchers are looking to an-
other source of funding—corporations.
Whether through sponsored research
agreements, innovative ideas about in-
vestment funds focused on science, or
Denmark’s tax model that allows the
Novo Nordisk Foundation to support
scientists, companies are picking up the
tab for science that’s not being covered
by public funds.
The Whitehead Institute for Biomedical
Research, in Cambridge, MA, for
instance, has turned to more sponsored
research to cover its overall research
budget, which has stayed at roughly
$60 million for the past decade, adjusting
for inflation. ‘‘Ten years ago themajority of
that funding came from federal sources,
and today it’s no more than a third,’’Celsays Richard Young, a member of the
institute who studies the regulatory cir-
cuitry that controls gene expression.
To make up for that drop in government
grants, the Whitehead looks to other
sources—philanthropy, royalties on pat-
ents, and sponsored research agree-
ments. Last year, for instance, Whitehead
announced it had signed a 3-year deal
in which the biotechnology company
Biogen would provide $5.25 million to
fund basic research in immunology,
neurology, developmental biology, ge-
netics, and genomics. ‘‘That’s basically
an R01 level of funding,’’ saysMarkMusk-
avitch, senior director of epigenetics at
Biogen, making Biogen’s support for a
given project comparable to the NIH’s.
He runs a consortium that also includes
researchers from Harvard Medical
School, Brigham and Women’s Hospital,
Institut Pasteur in Paris, and Washington
University in St. Louis, MO, and focuses
on the biology of neurodegeneration. Bio-
gen is also funding other consortia looking
at amyotrophic lateral sclerosis, sclero-
derma, fibrosis, and sickle cell anemia.
‘‘Biogen has been and wants to remain
an innovative company, and innovation
comes from research,’’ Muskavitch says.
These are not, he stresses, outsourced
corporate research and development
programs, aimed at producing products
for the company. ‘‘It’s not exactly blue
sky, but only secondarily are we trying
to move in limited cases into transla-
tional work,’’ he says. ‘‘We’re trying to
encourage basic research with an eye to-
ward translatability but not a requirement
for translation.’’
That said, the company is putting its
money into areas of biology where its
markets lie, such as treatment for Alz-
heimer’s or Parkinson’s disease. Muska-
vitch says in selecting the projects to
fund within the Whitehead, he has
‘‘encouraged but not constrained’’ the
researchers to lean toward neurobiology.
To receive Biogen funding, Whitehead
researchers go through a grant-writing
and approval process that’s similar to
applying for NIH money, though dealing
with the company is simpler than dealing
with the government, Young says.
‘‘I would say that relationship we have
with Biogen is probably an easier, more
friendly, more productive relationship
thana comparable onewithNIH,’’ he says.l 161, May 7, 2015 ª2015 Elsevier Inc. 699
Whitehead takes care to maintain inde-
pendence in its scientific work. If the Insti-
tute has a substantial financial interest in
a company, it won’t take funding from
that company. And none of the research
can be secret. ‘‘We have to be able to
publish what we learn. We can’t have a
restriction on publication,’’ Young says.
The same applies to government funding;
Whitehead won’t accept Department
of Defense funding that comes with publi-
cation restrictions.
What Whitehead does provide to fun-
ders is an advance look at research re-
sults, often for a 30-day period, as long
as that doesn’t delay publication. Under
some agreements, companies also have
a right of first refusal over any intellectual
property the Whitehead develops.
Another benefit to corporations that
sponsor research is developing relation-
ships with scientists who work in research
areas of interest to those companies.
‘‘Components of every major pharma are
here in the Boston area because they
want to be close to that human capital,’’
Young says.
In Denmark, the Novo Nordisk Founda-
tion also tries to use it funds to generally
support basic research and to develop
experts, while still having an eye on
advances that could benefit its areas of
specialization, which include diabetes,
hemophilia, and hormone replacement
therapy. ‘‘The overall goal of our grants
is we would like to develop what we
call a knowledge-based society,’’ says
Nauntofte. ‘‘We also want to help foster
a world class educational system.’’
The foundation provides grants
totaling 785 million Danish krone (US
$113 million), and plans to increase that
to 1.5 billion krone (US $216 million) by
2018. Half of that goes to support
health-related science, with focuses on
endocrinology and metabolic physiology.
Another 20% goes to biotechnology,
including finding newmethods for synthe-
sis and production. About 10% goes
to education and another 10% to human-
itarian purposes, even art history. And
roughly 4% goes to supporting research
that could lead researchers to start their
own companies. The foundation has es-
tablished centers for metabolic research,
biosustainability, protein research, and
basic stem cell biology. It also founded
the Danish National Biobank to collect700 Cell 161, May 7, 2015 ª2015 Elsevier Incbiological samples from the population
at large.
The Danish foundation structure is un-
usual, Nauntofte says. Foundations, often
created by the founders of successful
companies, actually own their companies
and receive tax benefits for giving away
a percentage of their profits. ‘‘Some of
our best-performing companies are
owned by private foundations and it’s
quite unique to our country,’’ Nauntofte
says. She estimates that approximately
80 percent of what Denmark spends on
research comes from the government
and about 10 percent comes from private
foundations. Another 7 percent comes
from European and American funding
agencies, with private companies cover-
ing the other 3 percent.
The Novo Nordisk Foundation main-
tains a controlling interest in the publicly
traded pharmaceutical company, Novo
Nordisk A/S, and Novozymes, a biotech-
nology company that manufactures en-
zymes. While the public company invests
in other life-science companies, the
foundation controls the grant process.
The process is similar to that of any fund-
ing agency, with calls for applications,
deadlines, and a review by a panel of
experts, none of whom can be Novo Nor-
disk employees. But once the award are
granted, Nauntofte says, there are no
strings attached. ‘‘They’re all donations,
they have no restrictions,’’ she says.
‘‘The researchers have full freedom. We
give the money away and it’s all theirs.’’
Søren Molin, a systems biologist at
the Technical University of Denmark,
in Lyngby, receives about $1 million of
funding a year as scientific director of
the bacterial cell factories section of the
foundation’s Center for Biosustainability.
‘‘We have the obligation in the contract
that we have to produce science of the
greatest impact and the greatest quality,’’
he says. ‘‘The other obligation we have is
to burn the money.’’ The recipients have
to spend the funds, not save or invest it
or return it to the foundation.
The center was created in 2010 after
the foundation approached the university
and asked them to propose a project
that could be labeled ‘‘biosustainability.’’
Beyond that initial direction, Molin says,
the foundation does not tell scientists
what work to do. ‘‘We are doing biotech
but not necessarily the kind of biotech.that Novo Science is doing,’’ Molin says,
though he adds, ‘‘Some of the research
and technology we’re doingmight be use-
ful and benefit the company eventually.’’
He doesn’t think the center, which will
receive nearly $160 million over 10 years,
would exist if it had to rely on Danish
funding agencies. ‘‘There would be no
way in this country that any research
council could spend this kind of money
toward a specific issue,’’ he says.
In countries that don’t have Denmark’s
tax structure, there are still creative ways
to funnel corporate cash into research.
Google, for instance, formed a biotech-
nology company, Calico, in 2013 to
focus on diseases of aging, including
neurodegeneration and cancer, with an
initial investment of $240 million and the
promise of up to another $490 million.
Calico hired Arthur Levinson, former
CEO of Genetech, to run the company
and brought other highly respected scien-
tists on board. Last year, Calico joined
forces with the biopharmaceutical com-
pany AbbVie to create an R&D collabo-
ration, with AbbVie contributing $750
million. Calico declined requests for an
interview. Meanwhile, Google’s research
arm, Google X, has a life sciences divi-
sion, which is developing wearable health
sensors and planning to collect genetic
and molecular information from thou-
sands of people. The Wall Street Journal
last July reported that the life sciences
division had built a team of 70 to 100
experts in areas such as physiology,
biochemistry, optics, imaging, and mo-
lecular biology.
But turning to individual companies
might not be the only way to find money
for science. Andrew Lo, a professor of
Finance at MIT’s Sloan School of Man-
agement, proposes creating investment
funds, not unlike the mutual funds in
which people invest their IRAs. There’s a
gap, he says, between the basic research
funded by the government, and poten-
tially marketable therapies, supported
by biopharmaceutical investors once
they’vemade it through Phase 2 of clinical
trials. He’d like to fill that gap with mega-
funds, large pools of investment dollars
that could support research in places
like the Whitehead.
Amegafund, Lo explains,might pick out
the top 50 or so biomedical research insti-
tutions in the country, and invest in five or
10 labs in each center. The labs could be
selected by an expert review committee,
and some could be culled from the fund
based on progress reports. Beyond that
review, the researchers would have free
rein, with the stipulation that if they
developed anythingmarketable, investors
would receive 8 percent of the royalties.
If such an investment produced only one
or two new multi-million-dollar drugs, it
would pay off handsomely. ‘‘It only takes
one or two cancer drugs to generate
profits, but you pay for all of the losses in
a diversified portfolio,’’ Lo says.
In a paper published in Nature Biotech-
nology in 2012, Lo ran a simulated fund
based on historical data from the previous
two decades and estimated that a fund
of $5 billion to $15 billion could generate
a return of anywhere from 5 to 12 percent,
depending on how it was set up. In a sepa-
rate simulation, he found that a megafund
taking advantage of orphan drug rules
could generate a return in double digits if
it invested $575 million in from 10 to 20
projects. He points to the Cystic FibrosisFoundation, which gave the drug com-
pany Vertex $150 million. Vertex devel-
oped a treatment for CF, and last year
the CF foundation sold the royalties from
that drug for $3.3 billion, which it can
now apply to further research.
‘‘It could be a more sustainable way
for science to become self-supporting,’’
says Lo, who expects that small versions
of a megafund could arise within the
coming year.
All this talk of corporate funding
may lead to worries about privatizing sci-
ence, with government leaving support
of research to the private sector. Molin,
for example, says that since he received
money from the Novo Nordisk Founda-
tion, it’s been harder for him to get grants
from Danish research councils—he does
better with European Union funders. ‘‘It’s
going to be an interesting situation to
see within say the next five years how
the balance will be between private and
public funding of research, Molin says.
‘‘If this balance is too biased in one direc-
tion, it’s not so healthy.’’CelNauntofte says that most policy-
makers realize that providing a stable
research and educational system is the
purview of federal governments. ‘‘The
idea is of course not to substitute for the
government, the idea of the foundation is
to make supplements,’’ she says.
Muskavitch doesn’t believe corporate
dollars can make up for lack of federal in-
vestment in research, and he worries
about the fact that investment has been
shrinking. ‘‘NIH has become dysfunc-
tional, and the scientific enterprise in the
US is at great risk going forward in re-
maining at the leading edge of biological
discovery and other discovery,’’ he
warns.
And Young argues that basic research,
which not only provides new discoveries
but also acts as an economic engine,
needs public support. ‘‘The federal gov-
ernment has the responsibility of ensuring
that that basic research is healthy,’’
Young says. ‘‘The system is really highly
dependent on the government recog-
nizing its role.’’Neil Savage
Lowell, MA
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